|Bid||11.80 x 4000|
|Ask||12.18 x 800|
|Day's Range||11.94 - 12.18|
|52 Week Range||8.27 - 17.62|
|Beta (3Y Monthly)||1.65|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Amicus or Portola: Which Is the Best Bet in May?(Continued from Prior Part)Vision for fiscal 2023In its investor presentation, Amicus Therapeutics (FOLD) has guided for revenues of around $200 million and $300 million for its AT-GAA Novel ERT
Amicus or Portola: Which Is the Best Bet in May?(Continued from Prior Part)Performance in the first quarterIn the first quarter, Amicus Therapeutics (FOLD) reported 150 net new patients using Galafold therapy, meaning the total number of patients
Amicus or Portola: Which Is the Best Bet in May?(Continued from Prior Part)First-quarter performanceIn the first quarter, Amicus Therapeutics (FOLD) reported non-GAAP EPS of -$0.39, a YoY fall of 39.29% and lower than the consensus estimate by
Amicus or Portola: Which Is the Best Bet in May?(Continued from Prior Part)Revenue guidanceIn its investor presentation, Amicus Therapeutics (FOLD) has guided for the revenues of its lead asset, Galafold, to fall in the range of $160 million to $180
Amicus or Portola: Which Is the Best Bet in May?Stock price movementsOn May 21, Amicus Therapeutics (FOLD) closed at $12.31, 3.97% higher than the previous close, 48.85% higher than the 52-week low of $8.27, and 30.14% lower than the 52-week high of
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -25.81% and -9.90%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Cranbury, New Jersey-based company said it had a loss of 56 cents per share. Losses, adjusted for non-recurring costs, came to 39 cents per share. The results fell short of Wall Street expectations. ...
Catalyst Pharma (CPRX) is expected to announce revenue results on its lead product, Firdapse, when it releases first-quarter 2019 earnings performance.
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's a roundup of top developments in the biotech space over the last 24 hours. Stock In Focus G1 Therapeutics Plans Regulatory Submission For Bone Marrow Preservation Drug G1 Therapeutics Inc (NASDAQ: ...
Amicus Therapeutics, Inc. (NASDAQ:FOLD) is a small-cap stock with a market capitalization of US$3.1b. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a k...
Amicus Therapeutics, Inc. (NASDAQ: FOLD ) has an extensive portfolio of novel therapies for rare diseases with a focus on lysosomal storage disorders, according to Janney Montgomery Scott. The Analyst ...
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
came up Wednesday night in the "Lightning Round" of Jim Cramer's entertaining and informative Mad Money program. Cramer said, "I think this one is really good. On-Balance-Volume (OBV) line turned stronger in late December.
The latest earnings announcement Amicus Therapeutics, Inc. (NASDAQ:FOLD) released in December 2018 confirmed that losses became smaller relative to the prior year's level as a result of recent tailwinds BelowRead More...
In another boost to Philadelphia’s standing as a cell and gene therapy hub, Cranbury, New Jersey-based Amicus Therapeutics said Tuesday it is establishing a new global research and gene therapy center at uCity Square, where the company expects to have 200 employees over the next few years. Amicus will occupy the top three floors — a total of 75,000-square-foot — at the new University City Science Center building at 3675 Market Street. An initial group of a couple dozen company employees has already moved into temporary space within the same complex at BioLabs@CIC Philadelphia.